JOURNAL OF MOLECULAR ENDOCRINOLOGY, published by BIOSCIENTIFICA LTD, is a prestigious academic journal that has made significant contributions to the fields of endocrinology and molecular biology since its inception in 1988. With an impressive impact factor that places it in the Q1 category for Endocrinology and Q2 for Molecular Biology, this journal is recognized for its rigorous peer-reviewed research that addresses key questions at the intersection of molecular mechanisms and hormonal regulation. The journal's accessibility within the Scopus rankings, notably positioned 45th out of 128 in Endocrinology, highlights its relevance and influence in shaping contemporary scientific discourse. Although the journal does not currently offer open access options, it remains an essential resource for researchers, professionals, and students eager to explore groundbreaking discoveries and advancements in the hormonal sciences. The JOURNAL OF MOLECULAR ENDOCRINOLOGY continues to pave the way for critical exploration and innovation, ensuring its place as a vital publication for the advancement of knowledge in molecular endocrinology.

BMC Endocrine Disorders is a leading open-access journal dedicated to advancing the field of endocrinology, diabetes, and metabolism. Published by BMC since 2001, this journal provides a vibrant platform for researchers to disseminate their findings across a wide array of topics related to endocrine health and disorders. With an impressive Q2 category ranking in both Endocrinology, Diabetes and Metabolism, and Medicine (miscellaneous) for 2023, it has positioned itself among the top-tier journals in its field, reflecting its commitment to high-quality research and discussions. The journal's accessibility enhances its reach and impact, ensuring that important findings are available to all stakeholders in the medical community. Researchers, healthcare professionals, and students alike will find valuable insights and updates that are crucial for both academic and practical applications within this dynamic field. The journal is actively welcoming submissions through 2024, facilitating continuous growth in the scientific discourse surrounding endocrine disorders.

EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

CYTOKINE is a prestigious peer-reviewed journal published by Academic Press Ltd - Elsevier Science Ltd, dedicated to advancing the field of immunology, biochemistry, and related biomedical sciences since its inception in 1989. With an ISSN of 1043-4666 and an E-ISSN of 1096-0023, this journal serves as a vital resource for researchers and professionals alike, offering cutting-edge research findings that delve into the roles and mechanisms of cytokines in health and disease. Recognized for its impactful contributions, CYTOKINE currently ranks in the Q2 quartile across several categories, including Biochemistry, Hematology, and Immunology, indicating its significant influence in these fields. Despite not offering open access, the journal maintains a high-quality standard, as evidenced by its robust Scopus rankings, including a notable 80th percentile in Medicine and Hematology. Researchers and students are encouraged to explore the latest findings and methodologies via CYTOKINE, as it continues to shape the future landscape of cytokine research and application.

Minerva Endocrinology, published by EDIZIONI MINERVA MEDICA in Italy, serves as a pivotal platform for advancing knowledge in the field of endocrinology, diabetes, and metabolism. With its ISSN 2724-6507 and E-ISSN 2724-6116, the journal has rapidly established a reputable position in academia, achieving impressive rankings such as Q3 in both Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as of 2023. This enables Minerva Endocrinology to attract a diverse readership, including researchers, healthcare professionals, and students committed to understanding the complexities of endocrine disorders. With annual publications covering breakthroughs and innovative research covering converged years from 2021 to 2024, the journal is devoted to facilitating the dissemination of high-quality studies that advance clinical and laboratory practices. Despite its >Open Access< status, the journal encourages submissions that reflect rigorous scientific inquiry and uphold the highest standards of scholarship, thereby enhancing its role as a significant contributor to the field of internal medicine and endocrinology.

Frontiers in Endocrinology, published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to the advancement of research in the fields of endocrinology, diabetes, and metabolism. Established in 2010, this journal has consistently demonstrated its academic excellence, achieving a prominent Q1 quartile ranking in its category as of 2023, and a commendable Scopus rank of #96 out of 244, placing it within the 60th percentile. The journal is committed to disseminating high-quality research that encompasses a wide range of topics within endocrinology, catering to the needs of a diverse audience that includes researchers, medical professionals, and students alike. With the critical goal of fostering knowledge-sharing and collaboration within the scientific community, Frontiers in Endocrinology is an invaluable resource for anyone looking to stay updated on the latest advancements and insights in endocrinology. It operates under a robust open-access model, ensuring that groundbreaking research is accessible to all, thereby driving innovation and progress in this essential field.

Austrian Journal of Clinical Endocrinology and Metabolism, published by SPRINGER WIEN, serves as a pivotal platform for the dissemination of research in the field of endocrinology, diabetes, and metabolism. With its ISSN 1998-7773 and E-ISSN 1998-7781, this journal has been contributing valuable insights to the field since its inception in 2010. Although it currently holds a Q4 ranking in the category of Endocrinology, Diabetes and Metabolism, it is committed to improving its impact factor by showcasing high-quality, peer-reviewed articles that reflect contemporary challenges and innovations in clinical endocrinology. Located in Vienna, Austria, the journal aims to provide researchers, healthcare professionals, and students with access to the latest findings and clinical practices that advance understanding and treatment of endocrine disorders. Researchers interested in submitting their work will find a supportive environment that embraces both experimental and clinical approaches. The Austrian Journal of Clinical Endocrinology and Metabolism is poised to become a valuable resource for those dedicated to improving health outcomes in metabolic disorders.

Endocrinology Diabetes and Metabolism Case Reports, published by BIOSCIENTIFICA LTD, stands as a pivotal forum for sharing significant advancements and clinical case studies in the fields of endocrinology, diabetes, and metabolism. With an Open Access model initiated in 2013, this journal encourages the widespread dissemination and accessibility of research findings, promoting collaboration and innovation among scholars and healthcare professionals. Based in the United Kingdom, the journal features a focus on practical applications and unique case reporting that enriches the clinical understanding and management of complex endocrine disorders. Though currently it's ranked in the Q3 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine, its ongoing commitment to quality and impact in clinical research makes it a valuable resource for researchers, professionals, and students alike, contributing to the advancement of knowledge in this critical medical domain.

Therapeutic Advances in Endocrinology and Metabolism is a premier open-access journal published by SAGE Publications Ltd that has established itself as a leading platform for research in the field of endocrinology, diabetes, and metabolism. With a commitment to disseminating high-quality research, the journal aims to advance our understanding of therapeutic interventions and innovations in the management of endocrine disorders. Since its inception in 2010, it has garnered a strong reputation, attaining a Q1 quartile ranking in 2023 in its category and boasting a respectable Scopus rank of #53 out of 244, positioning it within the 78th percentile. As an open-access journal since 2019, Therapeutic Advances in Endocrinology and Metabolism ensures that valuable research findings are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and students alike. The journal's multifaceted objectives encompass the publication of original research, reviews, and clinical studies that contribute to the evolving dialogue surrounding endocrine health. By delivering timely and robust content, it serves as an indispensable resource for those striving to make significant contributions to this vital area of medical science.